Veeva Systems Inc. (VEEV) Intrinsic Value & DCF Valuation
Software - Application · NYSE
Current Price
$317.82
Intrinsic Value
$391.47
+18.8% margin of safety
What Is Veeva Systems Inc.'s Intrinsic Value?
As of 2026-10-28, the base-case DCF model estimates the intrinsic value of Veeva Systems Inc. (VEEV) at $391.47 per share, compared with a market price of $317.82, a margin of safety of +18.8%. The base case assumes 12.3% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $328.77 to $462.47. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Is Veeva Systems Inc. (VEEV) Undervalued?
At $317.82, VEEV trades about 18.8% below the base-case intrinsic value estimate. That is a real discount, but it stays short of the 30% margin of safety required before calling a stock undervalued.
COMPETITIVE MOAT
↑Deep Life Sciences Ecosystem Lock-in
Veeva's integrated suite of cloud solutions for the life sciences industry creates significant switching costs. Customers are deeply embedded in its platform, making migration to competitors difficult and costly.
↑Data Network Effects in R&D
Veeva's Vault platform collects vast amounts of data across R&D processes. This data improves the platform's functionality and insights over time, creating a virtuous cycle that benefits all users.
↑Regulatory Compliance Expertise
Veeva's deep understanding and continuous adaptation to complex global regulatory requirements are critical. This specialized knowledge is difficult for competitors to replicate, providing a strong competitive edge.
INVESTMENT RISKS
↓Intensifying Competition in Cloud Solutions
The broader cloud software market is highly competitive. While Veeva has a niche, new entrants or established players could develop specialized offerings that challenge its dominance.
↓Customer Concentration in Pharma/Biotech
Veeva's primary customer base is concentrated within the pharmaceutical and biotechnology sectors. A significant downturn or consolidation within these industries could disproportionately affect Veeva's revenue.
↓Execution Risk on New Product Development
Continued growth relies on successful innovation and adoption of new products. Any missteps or delays in bringing new solutions to market could hinder its competitive position.
Base case
VEEV base case valuation
Intrinsic Value
$391.47
Margin of safety
+18.8%
Expected annual return
+4.3%
Base case assumptions: 12.3% annual growth, 10.0% discount rate, 30x exit multiple, 5 year projection. Data as of 2026-10-28.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the VEEV valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Veeva Systems Inc. respond.
Open DCF Calculator for VEEVCompany Overview
Veeva Systems Inc. is a leading provider of cloud-based software solutions, exclusively dedicated to the global life sciences industry. Its extensive operational presence spans across North America, Europe, the Asia Pacific region, the Middle East, Africa, and Latin America. The company's product portfolio is primarily structured around two major offerings. First, the Veeva Commercial Cloud delivers an integrated suite of software, data, and analytics tools designed to optimize commercial operations. This includes vital applications such as Veeva Customer Relationship Management (CRM) and its specialized Medical CRM, Veeva Closed Loop Marketing (CLM), sophisticated analytics via Veeva CRM MyInsights, approved email communication with Veeva CRM Approved Email, digital engagement tools like Veeva CRM Engage, commercial alignment through Veeva Align, event management capabilities with Veeva CRM Events Management, data warehousing solutions (Veeva Nitro), data services (Veeva OpenData, Veeva Link), master data management (Veeva Network), advanced analytical insights (Veeva Crossix, Veeva Data Cloud), and patient engagement platforms (MyVeeva for Patients). Secondly, Veeva Vault provides a robust collection of cloud-native enterprise content and data management applications. These applications are engineered to support both critical commercial functions—encompassing sales, marketing, and medical content and communications—and comprehensive research and development processes, including clinical trials, regulatory compliance, quality management, and patient safety. Beyond its software, Veeva offers a wide array of professional and support services. These range from strategic implementation and deployment planning, project management, and detailed requirements analysis to solution design and configuration. They also include system environment management and deployment, expert consulting for business process transformation related to Veeva solutions, technical guidance on data migration and systems integrations, comprehensive training programs, and ongoing managed services such as outsourced systems administration. Tracing its origins, the company was incorporated in 2007 as Verticals onDemand, Inc., and subsequently rebranded to Veeva Systems Inc. in April 2009. Its corporate headquarters are situated in Pleasanton, California.
Financial Metrics — VEEV Stock Valuation Data
Revenue/Share (TTM)
$21.30
FCF/Share (TTM)
$10.12
ROIC (TTM)
10.4%
ROE (TTM)
14.0%
P/FCF
31.3x
EV/EBITDA
38.4x
FCF Yield
3.19%
Debt/Equity
0.02x
Based on trailing twelve-month data, VEEV shows a free cash flow per share of $10.12 and a ROIC of 10.4%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 31.3x and FCF yield of 3.19% are important context metrics when evaluating VEEV's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of VEEV?
Veeva Systems Inc. currently generates $10.12 in free cash flow per share. At the current price of $317.82, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is VEEV undervalued?
VEEV trades at a P/FCF ratio of 31.3x with a free cash flow yield of 3.19%. This P/FCF is in a moderate range. However, whether VEEV is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value VEEV stock using DCF?
To perform a DCF valuation on Veeva Systems Inc.: (1) Start with the trailing free cash flow per share ($10.12) as the base, (2) project future FCF growth over 5-10 years based on Software - Application industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting VEEV's risk profile — with a debt-to-equity of 0.02x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to VEEV?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Veeva Systems Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Software - Application trends, then discounting those amounts to today's dollars. VEEV's ROIC of 10.4% shows moderate capital returns.
How does WACC affect VEEV stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For VEEV, with a debt-to-equity ratio of 0.02x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 38.4x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See VEEV PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Technology valuationsDCF and P/E value VEEV with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-10-28. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.